Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Revenue projections:

Revenue projections for BIIB
Revenue projections for BIIB

BIIB is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 2.679000
forwardPE 11.961437
debtToEquity 36.466000
earningsGrowth 0.000000
revenueGrowth -0.071000
grossMargins 0.789460
operatingMargins 0.196410
trailingEps 8.800000
forwardEps 15.944990

With a current ratio of 2.679, BIIB has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that BIIB is in a strong position to meet its immediate financial obligations without difficulty.
BIIB's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
BIIB's low earnings and revenue growth suggest that the company may see declining profits. This indicates potential financial challenges ahead, and could lead to a more cautious outlook from investors.
BIIB's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that BIIB is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for BIIB
Price projections for BIIB

BIIB's price has consistently been situated near the lower end of expected values. This ongoing trend may reflect investor skepticism about the company's growth potential and overall performance.

Insider Transactions:

Insider Transactions for BIIB
Insider Transactions for BIIB


6 BIIB transactions were recorded, when the market price was 154.4683354695638.2 purchases of BIIB were executed, with market price of 159.51499938964844.No distinct trend emerges from insider transactions, leaving uncertainty about whether these actions indicate a positive or negative outlook for the company.

Recommendation changes over time:

Recommendations trend for BIIB
Recommendations trend for BIIB


Analysts have been favoring BIIB with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning BIIB as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.